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Method and result: A 64-year-old male with standard indication for CRT
was referred to our institution for a CRT-D implantation. Unfortunately, intu-
bation of the CS was not possible. TEE showed a congenital CS anomaly with
complete drainage of the CS into the left atrium.
Because of contra-indication for general anaesthesia and thus for surgical epi-
cardial implantation, we proposed to implant the LV lead by a transseptal
approach.
After the patient had given his consent, a transseptal puncture was performed
via the right femoral vein. A conventional screw-in lead was implanted at the
laterobasal segment of the LV using a deflectable catheter guide introduced
via the left subclavian vein through the transseptal puncture. Post-implantation
parameters of the LV lead were acceptable: pacing threshold 0.7 V-0.4 ms,
impedance 435 ohms, R wave amplitude 5 mvolts. Right ventricular and right
atrium leads were then implanted (fig1)
A post-implant CT scan confirmed the ectopic location of the CS ostium
without persistent superior vena cava (fig 2).
The patient was discharged on anticoagulation with a targeted international
normalized ratio between 3 and 4. At the one- and three-month follow-up, no
complication had occurred. He was in class 2 of the NYHA and had not been
hospitalised. Electrical parameters remained steady.
Conclusion: Complete drainage of the CS in the left atrium without persis-
tent vena cava is a rare congenital abnormality. When cardiac resynchroniza-
tion therapy is needed, transseptal implantation could be a feasible alternative.
214
Gene-specific effect of beta-adrenergic blockade on QT duration in
the Long QT syndrome
Pierre Maison-Blanche, Isabelle Denjoy, Patrick De Jode, Anne Messali,
Ghassan Moubarak, Antoine Leenhardt
CHU Lariboisière, Département de Cardiologie, Paris, France
Background: In the long QT syndrome (LQTS) the clinical efficacy of
beta-blocker treatment differs according to the genotype. We aimed to asses
the effect of beta-blocker treatment in LQT1 and LQT2 patients.
Patients and methods: 24-hour Holter ECG were recorded before and
after beta-blocking therapy initiation in genotyped LQT1 (n=30, 8 males,
mean age 21±17) and LQT2 patients (n=16, 8 males, mean age 19±15). QT
duration was measured on consecutive 1-minute averaged QRS-T complexes
leading to up to 1440 QT-RR pairs for each recording. Then, we computed
subject- and condition-specific log/log QT/RR relationships which were used
to calculate QT interval duration at RR=1000 ms (QT1000=1000*).
Results: Before treatment,  coefficients were higher in LQT2 than in LQT1
patients (0.53±0.10 vs. 0.40±0.11, p<0.001) and QT1000 was longer in LQT2
than in LQT1 patients (521±38 vs. 481±39 ms, p<0.01). 
Beta-blockers significantly prolonged the mean RR interval (RR=827±161
ms before treatment and 939±197 ms on beta-blocker, p<0.0001). The  coef-
ficients were not significantly modified by beta-blockers (0.41±0.9 in LQT1
patients and 0.52±0.12 LQT2 patients). Beta-blocker treatment was associated
with a prolongation of the QT1000 interval (from 481±39 to 498±43 ms,
p<0.01) in LQT1 patients but with a shortening in LQT2 patients (from
521±38 to 503±32 ms, p<0.01).  
Conclusions: Our results confirm the elevated coefficient of the QT/RR
relationship in LQTS patients. LQT2 patients showed higher coefficient and
longer QT1000 when compared to LQT1 patients. The effect of beta-adren-
ergic blockade on QT1000 duration was gene-specific. Given the demon-
strated efficacy of beta-blockers in LQT1 and 2 patients, our data suggest that
QT1000 might be a poor predictor of outcome under anti-adrenergic therapy. 
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Accessory pathway (AP) refractory period (RP) increases from the youth to
the elderly. The large indications of AP ablation have changed the natural
follow-up. The purpose of the study was to report the clinical and electrophys-
iological data of pts with a Wolff-Parkinson White syndrome (WPW), studied
within 1 to 20 years of one another to evaluate the changes of these data. 
Methods: 2 baseline EPS were performed within 1 to 20 years  (y) of one
another (mean 9 y ± 4) in 61 pts, 37 males and 24 females, aged initially from
10 to 67 y (30±14), with a patent WPW. First electrophysiological study (EPS)
was indicated for syncope (n=6), atrioventricular reentrant tachycardias
(AVRT) (n=34), atrial fibrillation (AF) (n=5) or for asymptomatic preexcita-
tion (n= 16). The protocol was similar: the higher rate conducted through AP
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